Stem Cell Global Market Report 2024

The stem cell market size has grown strongly in recent years. It will grow from $13.97 billion in 2023 to $15.34 billion in 2024 at a compound annual growth rate (CAGR) of 9.8%. The growth in the historic period can be attributed to progress in regenerative medicine, a rise in the prevalence of chronic diseases, ongoing research and development initiatives, an increasing aging population, and the heightened awareness and acceptance of stem cell technologies.

The stem cell market size is expected to see rapid growth in the next few years. It will grow to $23.13 billion in 2028 at a compound annual growth rate (CAGR) of 10.8%. The growth in the forecast period can be attributed to the increasing applications in oncology, advancements in personalized medicine, support and funding from government initiatives, collaborative efforts and partnerships in biotechnology, along with the progression of clinical trials and regulatory approvals. Major trends in the forecast period include the commercialization of stem cell therapies, the utilization of CRISPR technology, the development of regulatory frameworks, investments in stem cell research, and a focus on exosome therapeutics.

The Stem cell market is experiencing growth due to the increasing prevalence of chronic diseases worldwide. Stem-cell therapy, involving the use of stem cells to treat or prevent diseases, has seen widespread application, with bone marrow transplants being the most commonly used method. Other therapies utilizing stem cells from umbilical cord blood are also in use. Currently, the transplantation of blood stem cells is widely employed to address diseases and conditions related to the blood and immune system or to restore the blood system post-treatments for specific cancers. For example, a report from January 2023 by the National Center for Biotechnology Information (NCBI) projects that the global number of people with chronic diseases will increase from 71.522 million in 2020 to 142.66 million by 2050.

The growth of the stem cell market is further fueled by the increasing demand for personalized medicine. Personalized medicine tailors medical treatment to an individual's unique genetic makeup, providing more precise and effective healthcare interventions. Stem cells, in the context of personalized medicine, offer the potential for regenerating and replacing damaged tissues, allowing for treatments tailored to individual patients. In 2022, the Food and Drug Administration’s Center for Drug Evaluation and Research (CDER) approved 37 new molecular entities (NMEs), with approximately 34% (12 of them) classified as personalized medicines by the Personalized Medicine Coalition (PMC). Thus, the rising demand for personalized medicine contributes to the growth of the stem cell market.

The growth of the stem cell market is hindered by the low acceptance rate for stem cell therapy treatments, particularly in the field of Embryonic stem cell therapeutics. Many of these treatments remain unproven in clinical trials and are considered highly experimental. Due to the experimental nature of these therapies, patients are often hesitant to undergo such treatments due to potential health, personal, and financial risks. For instance, individuals undergoing unproven or experimental treatments might become ineligible for future clinical trials or alternative treatment options. An illustrative example is a case in the USA where three elderly women were blinded after receiving stem cells derived from fat tissue at a clinic in Florida. These factors contribute to the limited adoption of stem cell therapies, thereby restraining the overall growth of the stem cell market.

Companies operating in the stem cell therapeutics market are concentrating on advancing technologies, such as Induced Pluripotent Stem Cells (IPSC), to enhance the effectiveness of stem cell therapies. IPSCs are derived from blood or skin cells that undergo reprogramming to achieve an embryonic-such as pluripotent state. This process involves the introduction of genes essential for maintaining key properties and promoting the growth of an unlimited source of any human cell type required for stem cell therapeutic purposes. Importantly, IPSCs are not derived from human embryos, addressing bioethical concerns and facilitating easier access to federal funding and support. An illustrative example is the Japanese company Oksara, which inaugurated a medicine center producing cells derived from IPSCs. Similarly, Takar Bio introduced human iPSC-derived Beta Cells, known as Cellartis, designed for disease modeling and drug discovery.

Major companies in the stem cell market are also prioritizing the development of automated stem cell analysis systems to gain a competitive advantage. These systems streamline the assessment of stem cell characteristics and viability, enhancing research and clinical applications with increased efficiency and precision. For instance, in May 2022, Beckman Coulter Inc., a US-based healthcare company, launched the AQUIOS STEM System, a solution specifically engineered for stem cell analysis. This system offers full automation, reducing hands-on time by 95% and minimizing error-prone tasks by 87.5%. Combining the automation capabilities of the AQUIOS CL with a stem cell enumeration solution, it can be customized to meet diverse requirements.

In August 2021, Catalent, a US-based provider of advanced delivery technologies, acquired RheinCell Therapeutics GmbH for an undisclosed amount. This strategic acquisition aims to leverage RheinCell's expertise in iPSC cell lines to enhance Catalent’s cell therapy portfolio, providing iPSC banks as a premium source for therapeutic development pathways to their customers. RheinCell Therapeutics GmbH, based in Germany, specializes in the GMP-compliant generation of human induced pluripotent stem cells (iPSCs).

Major companies operating in the stem cell market report are Danaher Corporation, Cryo-Cell International Inc., Daiichi Sankyo Company Limited, Lonza Group Ltd., PerkinElmer Inc., CellGenix GmbH, China Cord Blood Corporation, Organogenesis Holdings Inc., LifeCell International, AMAG Pharmaceuticals Inc., Cord Blood America Inc., StemCyte Inc., Cryoviva India, Cordlife Group Limited, Thermo Fisher Scientific Inc., CordVida, Cryo Stemcell Inc., Pluristem Therapeutics Inc., Mesoblast Limited, Americord Registry LLC, Smart Cells International, Athersys Inc., ReeLabs Pvt. Ltd., Cytori Therapeutics Inc., Esperite N.V., Stemade Biotech, ViaCord, Aldagen Inc., Isto Biologics, Brainstorm Cell Therapeutics Inc., Osiris Therapeutics Inc. North America was the largest region in the stem cell market in 2023. Western Europe was the second largest region in the global stem cell market share. The regions covered in the stem cell market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The primary product categories of stem cells include adult stem cells, human embryonic stem cells, induced pluripotent stem cells, and others. Adult stem cells represent a rare cell population in the body during the majority of postnatal life, capable of giving rise to a limited number of mature cell types that contribute to the formation of the tissue in which they are located. These stem cells can be derived from autologous or allogeneic sources and find applications in diverse areas such as regenerative medicine, drug discovery, and development.

The stem cell market research report is one of a series of new reports that provides stem cell market statistics, including stem cell market industry global market size, regional shares, competitors with a stem cell market share, detailed stem cell market segments, market trends and opportunities, and any further data you may need to thrive in the stem cell market industry. This stem cell market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The countries covered in the stem cell market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The stem cell market consists of sales of organoids & 3D Cell Culture, mesenchymal Stem Cells, neural stem cells, hematopoietic stem cells, and cancer stem cells. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.